5.59

3.45% -0.20

Lenz Therapeutics Inc (LENZ)

Overview News Price History Discussions Forecast

Lenz Therapeutics Inc stock is traded at $5.59, with a volume of 1.20M. It is down -3.45% in the last 24 hours and down -15.05% over the past month. LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.

Previous Close:

$5.79

Open:

$5.85

24h Volume:

1.20M

Relative Volume:

1.48

Market Cap:

$175.27M

Revenue:

$19.09M

Net Income/Loss:

$-82.13M

P/E Ratio:

-1.9946

EPS:

-2.8026

Net Cash Flow:

$-70.00M

1W Performance:

-5.09%

1M Performance:

-15.05%

6M Performance:

-62.41%

1Y Performance:

-83.68%

1-Day Range:

$5.3414

$5.86

1-Week Range:

$5.23

$6.21

52-Week Range:

$5.23

$50.40

Lenz Therapeutics Inc Stock (LENZ) Company Profile

Name

Lenz Therapeutics Inc

Sector

Healthcare (1096)

Industry

Biotechnology (616)

Phone

858-925-7000

Address

201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH

Employee

152

Twitter

Next Earnings Date

2026-07-29

Latest SEC Filings

LENZ's Discussions on Twitter

Compare LENZ vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LENZ Lenz Therapeutics Inc	5.59	175.27M	19.09M	-82.13M	-70.00M	-2.8026
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-14-25	Resumed	Piper Sandler	Overweight
Mar-18-25	Initiated	TD Cowen	Buy
Sep-27-24	Initiated	Raymond James	Outperform
Aug-12-24	Initiated	H.C. Wainwright	Buy
Apr-15-24	Initiated	Leerink Partners	Outperform
Apr-15-24	Initiated	William Blair	Outperform
Apr-10-24	Initiated	Citigroup	Buy
Mar-27-24	Initiated	Piper Sandler	Overweight
Feb-23-23	Downgrade	BofA Securities	Neutral → Underperform
Feb-23-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-23-23	Downgrade	Cowen	Outperform → Market Perform
Jan-25-23	Downgrade	BTIG Research	Buy → Neutral
Jan-18-23	Downgrade	BofA Securities	Buy → Neutral
Jan-06-23	Downgrade	BMO Capital Markets	Outperform → Market Perform
Jan-06-23	Downgrade	SVB Leerink	Outperform → Mkt Perform
Sep-15-22	Initiated	Cantor Fitzgerald	Overweight
Jun-17-22	Initiated	BMO Capital Markets	Outperform
Apr-14-22	Initiated	BTIG Research	Buy
Mar-22-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-18-22	Initiated	RBC Capital Mkts	Sector Perform
Jul-20-21	Initiated	Morgan Stanley	Overweight
Jul-20-21	Initiated	SVB Leerink	Outperform

View All

Lenz Therapeutics Inc Stock (LENZ) Latest News

Jul 11, 2026

LENZ Therapeutics (LENZ) Stock Fair Value Moves Lower As Analysts Reset Growth Assumptions - Yahoo Finance

Jul 11, 2026

Jul 09, 2026

Piper Sandler Maintains LENZ Therapeutics(LENZ.US) With Hold Rating, Maintains Target Price $12 - Moomoo

Jul 09, 2026

Jul 08, 2026

H.C. Wainwright Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Maintains Target Price $38 - Moomoo

Jul 08, 2026

LENZ Therapeutics Launches VIZZ Telehealth Prescribing Option for the Treatment of Presbyopia - VisionMonday.com

Jul 08, 2026

Jul 07, 2026

H.C. Wainwright reiterates Buy on LENZ Therapeutics stock on telehealth launch - Investing.com

Jul 07, 2026

LENZ Reiterates by HC Wainwright & Co. -- Price Target Maintained at $38 - GuruFocus

Jul 07, 2026